Francisco Martínez-Dubarbie, Sara López-García, Carmen Lage, Guglielmo Di Molfetta, Marta Fernández-Matarrubia, Ana Pozueta-Cantudo, María García-Martínez, Andrea Corrales-Pardo, María Bravo, Julio Jiménez-Bonilla, Remedios Quirce, Enrique Marco de Lucas, Marta Drake-Pérez, Diana Tordesillas, Marcos López-Hoyos, Juan Irure-Ventura, Elizabeth Valeriano-Lorenzo, Kaj Blennow, Nicholas J Ashton, Henrik Zetterberg, Eloy Rodríguez-Rodríguez, Pascual Sánchez-Juan
BACKGROUND: Plasma biomarkers of Alzheimer's disease (AD) constitute a non-invasive tool for diagnosing and classifying subjects. They change even in preclinical stages, but it is necessary to understand their properties so they can be helpful in a clinical context. OBJECTIVE: With this work we want to study the evolution of p-tau231 plasma levels in the preclinical stages of AD and its relationship with both cognitive and imaging parameters. METHODS: We evaluated plasma phosphorylated (p)-tau231 levels in 146 cognitively unimpaired subjects in sequential visits...
March 14, 2024: Journal of Alzheimer's Disease: JAD